Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.71 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376344 | 1.00 | PRKDC (1.00) | PRKDCPIK3CAMTORCREBBP | |
| SCHEMBL29499913 | 1.00 | PRKDC (1.00) | PRKDCPIK3CAMTORCREBBP | |
| SCHEMBL3753636 | 0.93 | PRKDC (0.86) | PRKDCPIK3CAMTORCREBBP | |
| SCHEMBL3756845 | 0.92 | PRKDC (0.85) | PRKDCPIK3CAMTORCREBBP | |
| SCHEMBL3755977 | 0.91 | PRKDC (0.84) | PRKDCPIK3CAMTORCREBBP | |
| SCHEMBL23157879 | 0.90 | PRKDC (0.81) | PRKDCPIK3CAMTORCREBBP | |
| SCHEMBL30405363 | 0.90 | PRKDC (0.81) | PRKDCPIK3CAMTORCREBBP | |
| SCHEMBL3753883 | 0.90 | PRKDC (0.81) | PRKDCPIK3CAMTOR | |
| SCHEMBL3755161 | 0.89 | PRKDC (0.80) | PRKDCPIK3CAMTOR | |
| SCHEMBL3760010 | 0.89 | PRKDC (0.80) | PRKDCPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11622965-B2 | Methods for treating lymphoid malignancies | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2023-04-11 | — | — | US | claimed |
| CN-112165945-A | Method of treating lymphoid malignancies | 浙江导明医药科技有限公司 | 2021-01-01 | — | — | CN | claimed |
| US-20200289517-A1 | Methods for Treating Lymphoid Malignancies | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2020-09-17 | — | — | US | claimed |
| EP-3700532-A1 | METHODS FOR TREATING LYMPHOID MALIGNANCIES | Zhejiang Dtrm Biopharma Co. Ltd. (CN) | 2020-09-02 | — | — | EP | claimed |
| EP-3471735-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang Dtrm Biopharma Co. Ltd. (CN) | 2019-04-24 | — | — | EP | claimed |
| WO-2017218844-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-12-21 | — | — | WO | claimed |
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3352755-B1 | TOPICAL COMPOSITION COMPRISING RAPAMYCIN FOR USE IN TREATING OR PREVENTING SEBORRHEIC KERATOSIS OR ACTINIC KERATOSIS | UNIV DREXEL (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250170133-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | MERCK SHARP & DOHME LLC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250136987-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4491184-A2 | CHANNEL MODULATORS | Auckland Uniservices Limited (NZ) | 2025-01-15 | — | — | EP | disclosed |
| EP-3183346-B1 | CHANNEL MODULATORS | AUCKLAND UNISERVICES LTD (NZ) | 2024-10-23 | — | — | EP | disclosed |
| US-20240325398-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20160177298-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20150320754-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2015-11-12 | — | — | US | disclosed |
| WO-2015160986-A2 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170133-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | BTK, SYK, LCK | PRKDC 15/4885PIK3CA 109/4885MTOR 35/4885 |
| US-11622965-B2 | Methods for treating lymphoid malignancies | BTK, BCL6, BCL6B | PRKDC 36/4885PIK3CA 322/4885MTOR 995/4885 |
| US-20200289517-A1 | Methods for Treating Lymphoid Malignancies | BTK, BCL6, BCL6B | PRKDC 36/4885PIK3CA 322/4885MTOR 995/4885 |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PRKDC 480/4885PIK3CA 16/4885MTOR 1/4885 |
| US-20150320754-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | PRKDC 548/4885PIK3CA 18/4885MTOR 24/4885 |
| US-20160177298-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | PRKDC 4037/4885PIK3CA 1019/4885MTOR 3059/4885 |
| US-20240325398-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | PRKDC 548/4885PIK3CA 18/4885MTOR 24/4885 |
| US-20250136987-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | PRKDC 4037/4885PIK3CA 1019/4885MTOR 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.